Our President & CEO Gilmore O’Neill discusses the evolution of gene editing, the potential of in vivo approaches, and the opportunity to develop durable, potentially one-time therapies for patients with serious diseases: Read here: https://bit.ly/4qnl7Nr. #biotech #leadership